Summary
Non-small cell lung cancer accounts for ~85% of all lung cancer cases, with incidence rising steadily.
The EGFR-mutant NSCLC landscape has progressed from 1st/2nd-generation EGFR TKIs (limited by T790M resistance, poor CNS penetration, and toxicity) to more effective 3rd-generation TKIs, with osimertinib leading; however, resistance mechanisms like C797S mutations persist.
Osimertinib (TAGRISSO) evolved from first-line monotherapy to adjuvant, locally advanced, and chemo-combination settings, extending treatment duration and becoming AstraZeneca’s multibillion-dollar “golden goose” and first-line standard of care.
Key ADC competitors include BMS’...
